Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Br J Dermatol. 2015 Feb 5;172(3):760–768. doi: 10.1111/bjd.13350

Proportion of transitional (IgD+/CD38++/CD27−) and memory (IgD+/CD38+-/CD27+) B cells in subjects treated with infliximab or placebo. Subjects treated with infliximab showed an increase in transitional B cells from week 18 thru week 26 compared to those treated with placebo (mean +/− SEM) (A). No change was seen in the mean proportion of memory B cells (B) during the study. Arrows signify infliximab or placebo infusion.

Proportion of transitional (IgD+/CD38++/CD27−) and memory (IgD+/CD38+-/CD27+) B cells in subjects treated with infliximab or placebo. Subjects treated with infliximab showed an increase in transitional B cells from week 18 thru week 26 compared to those treated with placebo (mean +/− SEM) (A). No change was seen in the mean proportion of memory B cells (B) during the study. Arrows signify infliximab or placebo infusion.